The Character Precision Medicine Platform

Our extensive data network powers drug development by prioritizing targets involved in disease progression pathways, optimizing clinical development design with patient stratification, and accelerating trial execution.

The Character Precision Medicine Platform

Our extensive data network powers drug development by prioritizing targets involved in disease progression pathways, optimizing clinical development design with patient stratification, and accelerating trial execution.
Patient and provider
network
Character Bio has built a robust patient and provider network from the ground up, directly partnering with individuals and clinicians who share their health data and experiences. This collaborative ecosystem ensures a trusted, transparent relationship that drives continuous engagement and supports more accurate, patient-centric discoveries.
‘Omics
We generate comprehensive multi-omics datasets—integrating genomics and stem cell-derived cellular models—to capture a more nuanced biological picture of each patient. By probing genetic and molecular layers using techniques like pathway-specific polygenic risk scores, we uncover deep insights into disease mechanisms and identify therapeutic targets for patient subgroups.
Longitudinal clinical data
Our approach incorporates longitudinal clinical data—electronic medical records, imaging, physician notes—collected over time to observe disease progression and response to interventions. This enriched historical perspective fuels predictive modeling and more informed therapeutic strategies.
AI-enabled phenotypes
Leveraging cutting-edge AI and computer vision tools, we identify subtle digital biomarkers from retinal images to track disease trajectories. Instead of modeling disease as simply present or absent, we model disease progression, offering a more nuanced view of disease states and potential intervention windows.
Fundus autofluorescence: geographic atrophy
Drug target selection
Discovery and validation of biological pathways and targets driving disease progression
Patient stratification
Develop and evaluate multimodal patient biomarkers
Clinical endpoint prioritization
Identify endpoints that best track patient disease progression and drug response
drug discovery and development
Learn more about our pipeline of genetically-supported therapeutic programs